Profile Image
David W. Hecht Photo
Name
David W. Hecht
Degree
M.D.
IDSA
Rank
Professor
Primary Department
Infectious Disease
Joint Department
Microbiology and Immunology
Appointment Request
Request an Appointment
Specialties
HIV
General Infectious Disease
AIDS
Locations
Loyola Outpatient Center
Certifications
Infectious Disease, American Board of Internal Medicine Subspecialty
American Board of Internal Medicine, Infectious Disease
Education
Medical School
Loyola University Chicago Stritch School of Medicine
Residencies
University of Minnesota Hospital and Clinics, Internal Medicine: General
Fellowships
Tufts University Affiliated Hospitals, Infectious Diseases
Publications
Kociolek,L. K.; Gerding,D. N.; Hecht,D. W.; Ozer,E. A.Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106 Microbes and Infection 2018 ;20(4):245-253
Kociolek,L. K.; Ozer,E. A.; Gerding,D. N.; Hecht,D. W.; Patel,S. J.; Hauser,A. R.Whole-genome analysis reveals the evolution and transmission of an MDR DH/NAP11/106 Clostridium difficile clone in a paediatric hospital The Journal of antimicrobial chemotherapy 2018 ; :
Ozer,E. A.; Hauser,A. R.; Gerding,D. N.; Espinosa,R. O.; Hecht,D. W.; Kociolek,L. K.Complete Genome Sequence of Clostridioides difficile Epidemic Strain DH/NAP11/106/ST-42, Isolated from Stool from a Pediatric Patient with Diarrhea Genome announcements 2017 ;5(38):10.1128/genomeA.00923-17
Snydman,D. R.; Jacobus,N. V.; McDermott,L. A.; Goldstein,E. J.; Harrell,L.; Jenkins,S. G.; Newton,D.; Patel,R.; Hecht,D. W.Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009 Anaerobe 2017 ;43:21-26
Hastey,C. J.; Boyd,H.; Schuetz,A. N.; Anderson,K.; Citron,D. M.; Dzink-Fox,J.; Hackel,M.; Hecht,D. W.; Jacobus,N. V.; Jenkins,S. G.; Karlsson,M.; Knapp,C. C.; Koeth,L. M.; Wexler,H.; Roe-Carpenter,D. E.; From the Ad Hoc Working Group on Antimicrobial Susceptibility Testing of Anaerobic Bacteria of CLSIChanges in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology Anaerobe 2016 ;42:27-30
Kociolek,L. K.; Gerding,D. N.; Osmolski,J. R.; Patel,S. J.; Snydman,D. R.; McDermott,L. A.; Hecht,D. W.Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients Antimicrobial Agents and Chemotherapy 2016 ;60(8):4896-4900
Gerding,D. N.; Hecht,D. W.; Louie,T.; Nord,C. E.; Talbot,G. H.; Cornely,O. A.; Buitrago,M.; Best,E.; Sambol,S.; Osmolski,J. R.; Kracker,H.; Locher,H. H.; Charef,P.; Wilcox,M.Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection The Journal of antimicrobial chemotherapy 2016 ;71(1):213-219
Soki,J.; Hedberg,M.; Patrick,S.; Balint,B.; Herczeg,R.; Nagy,I.; Hecht,D. W.; Nagy,E.; Urban,E.Emergence and evolution of an international cluster of MDR Bacteroides fragilis isolates The Journal of antimicrobial chemotherapy 2016 ; :
Park,M.; Deck,J.; Foley,S. L.; Nayak,R.; Songer,J. G.; Seibel,J. R.; Khan,S. A.; Rooney,A. P.; Hecht,D. W.; Rafii,F.Diversity of Clostridium perfringens isolates from various sources and prevalence of conjugative plasmids Anaerobe 2015 ;38:25-35
Wieczorkiewicz,J. T.; Lopansri,B. K.; Cheknis,A.; Osmolski,J. R.; Hecht,D. W.; Gerding,D. N.; Johnson,S.Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection (CDI) with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain, BI/NAP1/027 Antimicrobial Agents and Chemotherapy 2015 ; :
Miesel,L.; Hecht,D. W.; Osmolski,J. R.; Gerding,D.; Flattery,A.; Li,F.; Lan,J.; Lipari,P.; Polishook,J. D.; Liang,L.; Liu,J.; Olsen,D. B.; Singh,S. B.Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile Antimicrobial Agents and Chemotherapy 2014 ;58(4):2387-2392
Snydman,D. R.; Jacobus,N. V.; McDermott,L. A.; Golan,Y.; Goldstein,E. J.; Harrell,L.; Jenkins,S.; Newton,D.; Pierson,C.; Rosenblatt,J.; Venezia,R.; Gorbach,S. L.; Queenan,A. M.; Hecht,D. W.Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009 Anaerobe 2011 ;17(4):147-151
Park,M.; Rooney,A. P.; Hecht,D. W.; Li,J.; McClane,B. A.; Nayak,R.; Paine,D. D.; Rafii,F.Phenotypic and genotypic characterization of tetracycline and minocycline resistance in Clostridium perfringens Archives of Microbiology 2010 ;192(10):803-810
Snydman,D. R.; Jacobus,N. V.; McDermott,L. A.; Golan,Y.; Hecht,D. W.; Goldstein,E. J.; Harrell,L.; Jenkins,S.; Newton,D.; Pierson,C.; Rihs,J. D.; Yu,V. L.; Venezia,R.; Finegold,S. M.; Rosenblatt,J. E.; Gorbach,S. L.Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clinical Infectious Diseases 2010 ;50(Suppl 1):S26-33
Hurtuk,M. G.; He,L. K.; Szilagyi,A.; Gamelli,R. L.; Hecht,D. W.; Kennedy,R. H.; Rhys-Williams,W.; Love,W. G.; Shankar,R.The novel antibacterial drug XF-70 is a potent inhibitor of Staphylococcus aureus infection of the burn wound. Journal of Burn Care & Research 2010 ;31(3):462-469
Johnson,S.; Schriever,C.; Patel,U.; Patel,T.; Hecht,D. W.; Gerding,D. N.Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009 ;15(6):290-291
Sears,C. L.; Islam,S.; Saha,A.; Arjumand,M.; Alam,N. H.; Faruque,A. S.; Salam,M. A.; Shin,J.; Hecht,D.; Weintraub,A.; Sack,R. B.; Qadri,F.Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea. Clinical Infectious Diseases 2008 ;47(6):797-803
O'Connor,J. R.; Galang,M. A.; Sambol,S. P.; Hecht,D. W.; Vedantam,G.; Gerding,D. N.; Johnson,S.Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrobial Agents & Chemotherapy 2008 ;52(8):2813-2817
Thomas,J.; Hecht,D. W.Interaction of Bacteroides fragilis pLV22a relaxase and transfer DNA with Escherichia coli RP4-TraG coupling protein. Molecular microbiology 2007 ;66(4):948-960
Hecht,D. W.; Galang,M. A.; Sambol,S. P.; Osmolski,J. R.; Johnson,S.; Gerding,D. N.In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrobial Agents & Chemotherapy 2007 ;51(8):2716-2719
Hecht,D. W.; Kos,I. M.; Knopf,S. E.; Vedantam,G.Characterization of BctA, a mating apparatus protein required for transfer of the Bacteroides fragilis conjugal element BTF-37. Research in microbiology 2007 ;158(7):600-607
Barron,W. M.; Reed,R. L.; Forsythe,S.; Hecht,D.; Glen,J.; Murphy,B.; Lach,R.; Flores,S.; Tu,J.; Concklin,M.Implementing computerized provider order entry with an existing clinical information system. Joint Commission Journal on Quality & Patient Safety 2006 ;32(9):506-516
Barron,W. M.; Reed,R. L.; Forsythe,S.; Hecht,D.; Glen,J.; Murphy,B.; Lach,R.; Flores,S.; Tu,J.; Concklin,M.Information technology. Implementing computerized provider order entry with an existing clinical information system Joint Commission Journal on Quality & Patient Safety 2006 ;32(9):506-516
Vedantam,G.; Knopf,S.; Hecht,D. W.Bacteroides fragilis mobilizable transposon Tn5520 requires a 71 base pair origin of transfer sequence and a single mobilization protein for relaxosome formation during conjugation. Molecular microbiology 2006 ;59(1):288-300
Hecht,D. W.Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing Anaerobe 2006 ;12(3):115-121
Vedantam,G.; Hecht,D. W.Antibiotics and anaerobes of gut origin Current opinion in microbiology 2003 ;6(5):457-461
Hecht,D. W.; Osmolski,J. R.Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates. Antimicrobial Agents & Chemotherapy 2003 ;47(3):910-916